US Patent 7736861 Tivozanib response prediction
Patent 7736861 was granted and assigned to AVEO Pharmaceuticals on June, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+387 characters)
Article
Patent abstract
A diagnostic method for predicting whether a human tumor will be sensitive or resistant to treatment with tivozanib (AV-951) is disclosed. The method is based on measurement of macrophage content in a tissue sample from a tumor. Measurement of macrophage content can be based on analysis of macrophage marker gene expression, e.g., by RNA analysis or immunohistochemistry.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Bin Feng0
Feng Jiang0
Jie Lin0
Murray Robinson0
Xiaojian Sun0
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07736861 Tivozanib response prediction US Patent 7736861 Tivozanib response prediction
Infobox
Patent Number
077368610
Patent Number
77368610
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
077368610
Date of Patent
June 15, 2010
0Patent Application Number
126453550
Date Filed
December 22, 2009
0Official Website
Patent Primary Examiner
Edits on 3 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07736861 Tivozanib response prediction
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07736861
Date of patent
June 15, 2010
Patent application number
12645355
Date Filed
December 22, 2009
Patent primary examiner
Find more entities like US Patent 7736861 Tivozanib response prediction
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
